ARCA biopharma, Nuvelo in reverse merger
Executive Summary
Heart disease company ARCA biopharma is going public by merging with Nuvelo (cancer and cardiovascular diseases) in a stock swap. ARCA shareholders will own about 67% of the newly combined company, which will focus on cardiovascular therapeutics. The combination will take ARCA's name.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice